[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-330805-105":59,"doc-detail-330805-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multiple-primary-cancers-with-hematologic-malignancies-and-germline-predisposition-a-case-series","Multiple Primary Cancers With Hematologic Malignancies and Germline Predisposition - A Case Series","","Multiple primary (MP) cancers in the same patient are uncommon when they coexist with hematologic malignancies. This case series reports five patients diagnosed with MP cancers alongside hematologic malignancies, integrating clinical features, cytogenetic findings, and germline and somatic variant analyses. Two of five patients (40%) carried pathogenic or presumed germline variants in cancer predisposition genes. The second malignancies were hematologic and did not satisfy therapy-related myeloid neoplasm criteria. Germline testing is recommended when considering related donor stem cell transplantation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multiple-primary-cancers-with-hematologic-malignancies-and-germline-predisposition-a-case-series/330805/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multiple-primary-cancers-with-hematologic-malignancies-and-germline-predisposition-a-case-series/330805.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does “multiple primary (MP) cancers” mean in this study?","Question",{"text":112,"@type":113},"MP cancers refer to more than one cancer occurring in the same patient. The study distinguishes synchronous cancers within a six-month timeframe from metachronous cancers separated by more than six months.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the second primary cancers evaluated relative to therapy-related myeloid neoplasm?",{"text":117,"@type":113},"When the second primary cancer is hematologic, it can resemble therapy-related myeloid neoplasm. The study notes that, per WHO criteria, therapy-related myeloid neoplasm is tied to prior cytotoxic therapy and includes specific myeloid entities while excluding other categories.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is germline variant testing recommended here?",{"text":121,"@type":113},"Two of the five patients harbored pathogenic or presumed germline variants in cancer predisposition genes. The authors conclude that germline testing should be considered when MP cancers with hematologic malignancies raise considerations for related donor stem cell transplantation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},330805,1790397825,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52,"preview_page_count":4},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Brief Communication  \nDiagnostic Hematology  \nAnn Lab Med 2024;44:446-449  \n[https://doi.org/10.3343/alm.2023.0444](https://doi.org/10.3343/alm.2023.0444)  \nISSN 2234-3806 • eISSN 2234-3814  \nMultiple Primary Cancers With Hematologic Malignancies and Germline Predisposition:  \nA Case Series  \nJiwon Yun , M. D., Ph. D.1, Dong Soon Lee , M. D., Ph. D.2, Sungyoung Lee , Ph. D.3, and Hongseok Yun , Ph. D.3  \n1Department of Laboratory Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea; 2Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea; 3Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea  \nThe term “multiple primary (MP) cancers” refers to the existence of more than one cancer in the same patient. The combination of MP cancers with hematological malignancies is relatively uncommon. In this study, we present five patients diagnosed with MP cancers concomitant with hematological malignancies. We comprehensively analyzed their clinical characteristics, cytogenetic profiles, and germline and somatic variants. As first primaries, two patients had solid cancer not followed by cytotoxic therapy and three had hematologic cancer, followed by cytotoxic therapy. The second primaries were all hematologic malignancies that did not meet the criteria for therapy-related myeloid neoplasm. Notably, two (40%) out of the five patients harbored pathogenic potential/presumed germline variants in cancer predisposition genes. Therefore, germline variant testing should be considered when MP cancers with hematological malignancies require consideration for related donor stem cell transplantation.  \nKey Words: Germline predisposition, Hematologic neoplasms, High-throughput nucleotide sequencing, Multiple primary neoplasms  \nReceived: November 9, 2023  \nRevision received: December 15, 2023  \nAccepted: February 12, 2024  \nPublished online: March 7, 2024 Corresponding author:  \nHongseok Yun, Ph.D.  \nDepartment of Genomic Medicine, Seoul National University Hospital,  \n101 Daehak-ro, Jongno-gu, Seoul 03080, Korea  \nE-mail: [hs.yun@snu.ac.kr](hs.yun@snu.ac.kr)  \n© Korean Society for Laboratory Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://creativecom](https://creativecom)[mons.org/licenses/by-nc/4.0](mons.org/licenses/by-nc/4.0)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nThe term “multiple primary (MP) cancers” refers to the occurrence of more than one synchronous or metachronous cancer in the same patient [1] .“Synchronous cancers” refer to the occurrence of MP cancers within a six-month timeframe, whereas“metachronous cancers” describe the development of MP cancers with more than a six-month gap between their occurrences [2] . The definition of MP cancers is established based on two guidelines: the criteria of the Surveillance Epidemiology and End Results (SEER) Program [3] and those of the International Association of Cancer Registries (IACR) and the International Agency for Research on Cancer (IARC) [4, 5] . The estimated incidence of MP tumors ranges from 2%–17%[6-9] . Among MP cancer cases, breast and colorectal cancers are the most frequently  \nobserved, with the most common tumor combination being breast and colorectal cancer [10] . The combination of MP cancers with hematological malignancies is rare [2] .  \nIn patients with MP cancers and hematological malignancies, cases in which second primary cancer is a hematologic malignancy can be confused with therapy-related myeloid neoplasm (T-MN). According to the 4th edition of the WHO diagnostic criteria [11], T-MN is a late complication that occurs following cytotoxic therapies, including chemotherapy and radiotherapy, and includes myelodysplastic neoplasms (MDS), myelodysplastic/ myeloproliferative neopl","cbCaioxBDkGQfSg0","https://ap.wps.com/l/cbCaioxBDkGQfSg0","pdf",398752,"English","# Diagnostic Hematology\n## Multiple Primary Cancers With Hematologic Malignancies and Germline Predisposition - A Case Series\n## Key Concepts and Case Selection Criteria\n## Interpretation Against Therapy-Related Myeloid Neoplasm Criteria\n## Germline Predisposition and Testing Implications","[{\"question\":\"What does “multiple primary (MP) cancers” mean in this study?\",\"answer\":\"MP cancers refer to more than one cancer occurring in the same patient. The study distinguishes synchronous cancers within a six-month timeframe from metachronous cancers separated by more than six months.\"},{\"question\":\"How were the second primary cancers evaluated relative to therapy-related myeloid neoplasm?\",\"answer\":\"When the second primary cancer is hematologic, it can resemble therapy-related myeloid neoplasm. The study notes that, per WHO criteria, therapy-related myeloid neoplasm is tied to prior cytotoxic therapy and includes specific myeloid entities while excluding other categories.\"},{\"question\":\"Why is germline variant testing recommended here?\",\"answer\":\"Two of the five patients harbored pathogenic or presumed germline variants in cancer predisposition genes. The authors conclude that germline testing should be considered when MP cancers with hematologic malignancies raise considerations for related donor stem cell transplantation.\"}]","Multiple Primary Cancers With Hematologic Malignancies and Germline Predisposition - A Case Series | PDF",1789990228]